Abstract
The clinical presentation of heart disease is different between men and women and this distinction is pivotal for a correct diagnosis and an adequate treatment. However, the definition of symptoms classically associated with heart disease is mainly based on the characteristics of those reported in men. Chest pain or chest discomfort in women are therefore often regarded as “atypical” and these symptoms tend to be misdiagnosed and under- treated. Further, women are less likely to receive appropriate invasive and non invasive investigations. They are less likely to refer for medical help and tend to present late in the process of the cardiovascular disease, with delays in the start of effective treatment. Therefore, a gender-specific assessment of cardiovascular risk is strongly advised for patients presenting with symptoms suggestive of heart disease.
Keywords: Coronary disease, angina, heart disease, women, misdiagnosed, symptomatology, atypical, palpitations, dyspnea, scapula, angiograms, prognosis, dyslipidemia, atherogenic, stratification, diastolic, systolic, intramural
Current Pharmaceutical Design
Title: Gender Differences in the Clinical Presentation of Heart Disease
Volume: 17 Issue: 11
Author(s): Peter Collins, Cristiana Vitale, Ilaria Spoletini and Giuseppe Barbaro
Affiliation:
Keywords: Coronary disease, angina, heart disease, women, misdiagnosed, symptomatology, atypical, palpitations, dyspnea, scapula, angiograms, prognosis, dyslipidemia, atherogenic, stratification, diastolic, systolic, intramural
Abstract: The clinical presentation of heart disease is different between men and women and this distinction is pivotal for a correct diagnosis and an adequate treatment. However, the definition of symptoms classically associated with heart disease is mainly based on the characteristics of those reported in men. Chest pain or chest discomfort in women are therefore often regarded as “atypical” and these symptoms tend to be misdiagnosed and under- treated. Further, women are less likely to receive appropriate invasive and non invasive investigations. They are less likely to refer for medical help and tend to present late in the process of the cardiovascular disease, with delays in the start of effective treatment. Therefore, a gender-specific assessment of cardiovascular risk is strongly advised for patients presenting with symptoms suggestive of heart disease.
Export Options
About this article
Cite this article as:
Collins Peter, Vitale Cristiana, Spoletini Ilaria and Barbaro Giuseppe, Gender Differences in the Clinical Presentation of Heart Disease, Current Pharmaceutical Design 2011; 17 (11) . https://dx.doi.org/10.2174/138161211795656927
DOI https://dx.doi.org/10.2174/138161211795656927 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Direct Interaction Between Mitochondrial Proteins and Amyloid-β Peptide and its Significance for the Progression and Treatment of Alzheimer’s Disease
Current Medicinal Chemistry Exercise and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Oxidative Stress in the Cochlea: An Update
Current Medicinal Chemistry Outcomes of Anticoagulant Therapy with Low-Molecular-Weight Heparin (LMWH) and Warfarin for Thromboangiitis Obliterans (TAO)
Current Vascular Pharmacology Inflammation in Ischemic Stroke Subtypes
Current Pharmaceutical Design Recent Patents on Implantable Drug/Protein Delivery Systems Fabricated Using Electrospinning
Recent Patents on Biomedical Engineering (Discontinued) Targeting Monoamine Oxidases with Multipotent Ligands: An Emerging Strategy in the Search of New Drugs Against Neurodegenerative Diseases
Current Medicinal Chemistry Lysophosphatidic Acid and Ischemic Stroke
Vascular Disease Prevention (Discontinued) Obesity, Metabolic Syndrome, Diabetes and Arterial Hypertension
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nonalcoholic Fatty Liver Disease and Cardiovascular Disease
Current Pharmaceutical Design Recent Insights into the Role of Prostanoids in Atherosclerotic Vascular Disease
Current Vascular Pharmacology Episcleritis and Scleritis in Rheumatic Disease
Current Rheumatology Reviews Endogenous Cardioprotective Agents: Role in Pre and Postconditioning
Current Drug Targets Body Mass Index (BMI) and Cognitive Functions in Later Life
Current Alzheimer Research Pharmacological Interventions on Asymmetric Dimethylarginine, a Clinical Marker of Vascular Disease
Current Medicinal Chemistry Current Algorithms for the Diagnosis of wide QRS Complex Tachycardias
Current Cardiology Reviews Role of Physician Gender in the Quality of Care of Cardiometabolic Diseases
Current Pharmaceutical Design Editorial [Hot topic: Current Topics on Hypolipidaemic Therapy and Cardiovascular Risk Assessment (Guest Editors: Evangelos C. Rizos and Moses S. Elisaf)]
Current Vascular Pharmacology Hypertensive Cardiomyopathy in Asymptomatic Patients: A Neglected Diagnosis
Current Hypertension Reviews An Insight of Novel Pharmacological Therapies in Hypertrophic Cardiomyopathy
Medicinal Chemistry